REVELATION BIOSCIENCES, INC. Net Income (Loss) Available to Common Stockholders, Basic
REVELATION BIOSCIENCES, INC. (REVB) reported Net Income (Loss) Available to Common Stockholders, Basic of -$3.32 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-06
- REVELATION BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$3.32M.
- REVELATION BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$8.69M.
- REVELATION BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$2.51M.
- REVELATION BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$4.68M.
- REVELATION BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for fiscal 2025 was -$14.87M.
- REVELATION BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was -$15.04M.
- REVELATION BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for fiscal 2021 was $6.90K.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.32M 10-Q · filed 2026-08-06 | -$12.01M 10-Q · filed 2026-08-06 | -$14.53M derived: sum of 3 quarters · filed 2026-08-06 | -$19.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$8.69M 10-Q · filed 2026-05-07 | -$11.20M derived: sum of 2 quarters · filed 2026-05-07 | -$15.88M derived: sum of 3 quarters · filed 2026-05-07 | -$21.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$2.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$7.19M derived: sum of 2 quarters · filed 2026-02-26 | -$12.81M derived: sum of 3 quarters · filed 2026-08-06 | -$14.87M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$4.68M 10-Q · filed 2025-11-06 | -$10.30M derived: sum of 2 quarters · filed 2026-08-06 | -$12.35M 10-Q · filed 2025-11-06 | -$14.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$5.63M 10-Q · filed 2026-08-06 | -$7.68M 10-Q · filed 2026-08-06 | -$9.40M derived: sum of 3 quarters · filed 2026-08-06 | -$11.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$2.05M 10-Q · filed 2026-05-07 | -$3.78M derived: sum of 2 quarters · filed 2026-05-07 | -$6.02M derived: sum of 3 quarters · filed 2026-05-07 | -$14.41M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$3.97M derived: sum of 2 quarters · filed 2026-02-26 | -$12.36M derived: sum of 3 quarters · filed 2026-02-26 | -$15.04M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$2.24M 10-Q · filed 2025-11-06 | -$10.63M derived: sum of 2 quarters · filed 2025-11-06 | -$13.31M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$8.39M 10-Q · filed 2025-08-08 | -$11.07M 10-Q · filed 2025-08-08 | ||
| 2021-12-31 | $1.17K derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-15 | $3.02K derived: sum of 2 quarters · filed 2022-04-15 | $4.86K derived: sum of 3 quarters · filed 2022-04-15 | $6.90K 10-K · filed 2022-04-15 |
| 2021-09-30 | $1.85K 10-Q · filed 2021-10-29 | $3.69K derived: sum of 2 quarters · filed 2021-10-29 | $5.72K 10-Q · filed 2021-10-29 | |
| 2021-06-30 | $1.83K 10-Q · filed 2021-08-23 | $3.65K 10-Q · filed 2021-08-23 | ||
| 2021-03-31 | $2.04K derived: 10-K 12 month − 3 quarters · filed 2022-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |